Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study.
- 28 June 1975
- Vol. 2 (5973) , 714-715
- https://doi.org/10.1136/bmj.2.5973.714
Abstract
L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. To test the potential value of L-dopa in this disease a randomized clinical trial of L-dopa and nafoxidine (as the reference compound) was conducted in postmenopausal women with advanced breast cancer. Objective remissions were obtained in sever out of 36 patients (19%) treated with nafoxidine but in none out of 40 patients treated with L-dopa. L-Dopa in the dose schedule used seems to be ineffective in advanced breast cancer.Keywords
This publication has 9 references indexed in Scilit:
- Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.BMJ, 1975
- PLASMA-PROLACTIN IN HUMAN BREAST CANCERThe Lancet, 1974
- The response of breast cancer patients with bone pain to L-dopaCancer, 1974
- Effects of 2-Br-α-ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal womenPublished by Elsevier ,1973
- PROLACTIN, F.S.H., AND L.H. IN BREAST CANCER: EFFECT OF LEVODOPA AND OOPHORECTOMYThe Lancet, 1972
- BRAIN CATECHOLAMINES AND BREAST CANCER: A HYPOTHESISThe Lancet, 1972
- Levodopa Suppression of Prolactin in Nonpuerperal GalactorrheaNew England Journal of Medicine, 1971
- Prolactin and mammary gland carcinogenesis. The problem of human prolactinInternational Journal of Cancer, 1970
- Prolactin-dependent rat mammary cancer: a model for man?1969